Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.73) by 19.18 percent. This is a 1.14 percent increase over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $887.000 thousand which missed the analyst consensus estimate of $7.267 million by 87.79 percent. This is a 91.11 percent decrease over sales of $9.977 million the same period last year.